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Abstract
Background: Tartrate-resistant acid phosphatase (TRAP) is a metalloprotein enzyme that belongs
to the acid phosphatases and is known to be expressed by osteoclasts. It has already been
investigated as a marker of bone metastases in cancer patients. In this study, which examined the
value of serum TRAP concentrations as a marker of bone disease in breast cancer patients, we
observed high concentrations of TRAP even in patients without bone metastases. To elucidate this
phenomenon, we examined the expression of TRAP in breast cancer cells and the cells of several
other malignancies.
Methods: TRAP concentrations in the serum of tumor patients were determined by ELISA. The
expression of TRAP in breast, ovarian, and cervical cancer and malignant melanoma was analyzed
by immunohistochemistry. RT-PCR and immunocytology were used to evaluate TRAP expression
in cultured tumor cells.
Results: A marked increase in serum TRAP concentrations was observed in patients with breast
and ovarian cancer, regardless of the presence or absence of bone disease. TRAP expression was
found in breast and ovarian cancers and malignant melanoma, while cervical cancer showed only
minimal expression of TRAP. Expression of TRAP was absent in benign tissue or was much less
marked than in the corresponding malignant tissue. TRAP expression was also demonstrated in
cultured primary cancer cells and in commercially available cell lines.
Conclusion: Overexpression of TRAP was detected in the cells of various different tumors. TRAP
might be useful as a marker of progression of malignant disease. It could also be a potential target
for future cancer therapies.
Background
Tartrate-resistant acid phosphatase (TRAP) is a metallo-
protein enzyme belonging to the family of acid phos-
phatases, which are specifically grouped together because
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of their ability to catalyze the hydrolysis of orthophos-
phate monoesters under acidic conditions. TRAP has been
studied extensively as a marker of bone disease in cancer
patients [1-6]. It is normally found at low concentrations
in the peripheral blood [7]. An increase in osteoclast activ-
ity is accompanied by synthesis and secretion of TRAP and
serum TRAP activity is enhanced in the presence of
increased bone resorption [8]. Elevated TRAP concentra-
tions are found under pathological conditions such as
Paget's disease, primary and secondary hyperparathy-
roidism, severe osteoporosis, and multiple myeloma, and
in the presence of bone metastases originating from breast
cancer and other malignancies [9,10].
These observations suggest that acid phosphatases might
be diagnostically useful as serological and histological
markers of progression and that they might also be of use
in the investigation of the corresponding pathophysiolog-
ical process. TRAP has been used as a diagnostic marker
for hairy cell leukemia for more than two decades [1]. To
clarify the significance of this enzyme in solid tumors, we
investigated serum TRAP concentrations in patients with
breast and ovarian cancers and the expression of TRAP in
the primary tumors of patients with breast, ovarian or cer-
vical cancer or malignant melanoma, and cultured cells
from effusions/ascites associated with such tumors.
Expression of the TRAP protein or mRNA were evaluated,
rather than TRAP activity.
Methods
Ethics
The experimental research and the collection of patients'
cells, tissue, and serum for the study was approved by the
Ethics Committee of the Medical Faculty of the University
of Wuerzburg, Germany, reference number 139/00. All
patients participating in the study gave written informed
consent.
1. Serum and tissue samples
Serum samples were collected from patients with breast (n
= 34) and ovarian (n = 39) cancer and from 37 controls,
of whom 17 were premenopausal and 20 were postmen-
opausal (Table 1). A history of medications or conditions
that could possibly affect bone metabolism (e.g. oste-
oporosis, thyroid disease, fractures, rheumatoid arthritis,
osteoarthritis, steroid treatment) resulted in exclusion
from the control group. Biopsy specimens of breast (n =
21), ovarian (n = 8) and cervical (n = 7) cancer, malignant
melanoma (n = 6), benign breast tissue (n = 2), normal
ovarian tissue (n = 3), and normal skin (n = 3) were inves-
tigated for TRAP expression by immunohistochemistry.
13 of the 34 breast cancer patients, but none of the ovar-
ian cancer patients, had metastatic bone disease.
2. Cell cultures
Primary tumor cells from malignant pleural effusions and
ascites associated with metastatic breast cancer (4 cases)
and ovarian cancer (4 cases) were isolated and cultured.
The effusions had been aspirated because of clinical symp-
toms. The aspirates (20–500 ml) were centrifuged, and
the resulting cell pellets washed twice in phosphate buff-
ered saline (PBS, Biochrom, Berlin, Germany). Cells were
cultured in HBCA medium [12] supplemented with 10%
fetal bovine serum (FBS, PAA Laboratories, Cölbe, Ger-
many) and gentamycin (50 μg/ml, Biochrom) at 2 × 105
cells/ml in a plastic cell-culture flask in a humidified incu-
bator (atmosphere of 5% CO2). Contaminating fibrob-
lasts were eliminated by trypsin treatment every other day
and the remaining tumor cell monolayer was cultured
until the cells were of homogeneous morphology (pas-
sage 3–4). If the tumor cells had divided adequately, con-
taminating leukocytes and fibroblasts were absent after
these few passages.
The following commercially available cell lines were also
investigated: Breast cancer cell lines MCF7, MDA-MB-468,
BT20, and HBL-100, ovarian cancer cell lines OAW42 and
SKOV3, and cervical cancer cell lines SiHa and CaSki. The
breast and ovarian cancer cell lines were obtained from
Cell Line Services (Heidelberg, Germany) and cervical
cancer cell lines from the Department of Obstetrics and
Gynecology, University of Jena, Germany. All cell lines
were cultured in RPMI1640 medium (Biochrom) supple-
mented with 10% FBS and gentamycin (Biochrom).
3. Enzyme-Linked Immunosorbent Assay (ELISA)
The serum samples were analyzed using a TRAP-ELISA Kit
(Medac, Wedel, Germany) according to the manufac-
turer's instructions. The range of the ELISA was 1–10 U/l.
In some cases the TRAP concentration was higher than 10
U/l: these samples were diluted 1:4 in the sample dilution
buffer provided with the kit and reanalyzed. Final serum
concentrations were then derived by multiplication of the
value obtained by four.
4. Immunohistochemistry and immunocytology
Immunocytological investigations were performed on the
cells cultured from the malignant pleural effusions and
ascites and commercially available established cell lines.
Cells were seeded onto APES-(3-amino-propyltriethoxy-
silane; Roth, Karlsruhe, Germany) coated slides and
grown over night. They were then fixed with 4% formalin
and washed in PBS for 10 min, followed by distilled water
for 2 minutes and then acetone/methanol [1:2 for 5 min].
For immunohistochemistry, sections of routinely-proc-
essed paraffin-embedded tissue were cut at 2–3 μm,
placed onto APES-coated slides, dewaxed in xylene, and
rehydrated in graded ethanols and TRIS-buffered salineBMC Cancer 2006, 6:199 http://www.biomedcentral.com/1471-2407/6/199
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(TBS; 25 mM TRIS/HCl, pH 7.4, 137 mM NaCl, 2.7 mM
KCl). For antigen retrieval, sections were subjected to heat
pretreatment by boiling in 0.01 M sodium citrate buffer
(pH 6.0) for 10 min in a microwave oven (600 Watt/sec.).
For specific detection of the TRAP antigen, the sections
and cell smears were incubated with goat serum for 30
min and then with the TRAP monoclonal antibody at
1:100 dilution in antibody diluent (DAKO, Hamburg,
Germany). The TRAP antibody is directed against the N-
terminal portion of human TRAP (clone: 26E5, subtype:
IgG2b; Novocastra Laboratories Ltd., Newcastle, United
Kingdom). After one wash in PBS, the horseradish-perox-
idase (HRP)-labeled rabbit anti-mouse specific secondary
antibody (DAKO, dilution 1:100) was applied. The detec-
tion reaction was developed with 3,3'-diaminobenzidine
(DAB; Sigma, Deisenhofen, Germany) or Vector VIP (Vec-
tor Laboratories, Burlingame, CA, USA). The sections and
smears were counterstained with hematoxylin (Mayers,
Sigma), dehydrated through graded ethanols, and embed-
ded in Entelan (Merck, Darmstadt, Germany).
Immunoreactivity of the cells and tissues was evaluated by
comparison with control sections incubated with an IgG
control antibody. They were rated positive [+] if a clear
brown or purple color was detected in the majority of the
cells, as weakly positive [(+)] if less than 50% of the cells
were stained (the majority weakly)), and as negative [-] if
no staining was detectable.
5. RT-PCR
RNA was extracted from the cell lines obtained from the
patients and from the commercial cell lines using the Qui-
agen RNA-extraction kit (Quiagen, Hamburg, Germany).
LPS-activated dendritic cells, which have been described
to express TRAP [13], and JAR choriocarcinoma cells
served as negative controls, respectively. mRNA was tran-
scribed with reverse transcriptase and oligo T-primers
(both from Promega, Mannheim, Germany). 5 μg of
cDNA were used for PCR. Two different sets of primers,
which were designed specifically to amplify mRNA of
human TRAP 5b, were used. Both gave identical results.
The first set had the following sequences: upstream-
primer 3'CTTTCTACCGCCTGCACTTC5', and down-
stream primer 3'GCTGTTTCTTGAGCCAGGAC5'. The sec-
ond primer pair consisted of the upstream primer
3'AGGCTTTTCCTCCAACCTGT5' and downstream
primer: 3'GGAACTCAGCAAAGGTGAGC5', Taq polymer-
ase (Promega) was used at 1 U/μl in the buffer supplied
by the manufacturer with 5 mM dNTP and 25 mM MgCl2.
The PCR was run for 40 cycles and the temperatures were
96°C, 60°C (annealing), and 72°C. The PCR products
corresponding to the mRNA were 171 and 175 base pairs
in size for the two different primer pairs respectively. PCR
products were run on a 1% agarose gel and analyzed. RT-
PCR was considered positive when a clear band of the
expected size was visible on an ethidium bromide-stained
gel.
Results
1. Enzyme-Linked Immunosorbent Assay(ELISA)
TRAP 5b in the serum of tumor patients and controls
The median values for serum TRAP concentrations are
summarized in Table 1 and Figure 1. Serum from breast
and ovarian cancer patients as well as controls were ana-
lyzed by ELISA. The TRAP concentration was above the
detection limit in all the samples analyzed. Four of the
samples from patients with visceral and bone metastases
showed concentrations above the upper standard and the
final concentration was therefore calculated from diluted
samples.
We first evaluated serum from 14 breast cancer patients
who had visceral metastases only, and found increased
values (median 4.0) in almost all of these patients as com-
pared to the control group as a whole (median 3.2) (Table
1). The values were comparable to those in patients with
metastases confined to the bones. Interestingly, the high-
est serum concentrations were found in patients with
aggressive disease, with both bone and visceral metastases
(median 10) (Table 1).
Table 1: Median TRAP -concentrations in serum
diagnosis no. of patients metastases median c [TRAP] U/l
breast cancer 7 bone and visceral 10
breast cancer 7 only liver 5.0
breast cancer 6 only bone 4.1
breast cancer 14 only visceral 4.0
ovarian cancer I 13 visceral 3.7
ovarian cancer II 26 visceral 1.9
control pre-menopausal 17 - 2.6
control post-menopausal 20 - 3.4
total control group 37 - 3.2BMC Cancer 2006, 6:199 http://www.biomedcentral.com/1471-2407/6/199
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Serum TRAP protein concentrations in 40 ovarian cancer
patients with advanced disease were also determined.
Analysis revealed that there were essentially two groups of
ovarian cancer patients: one with high serum TRAP con-
centrations (median 3.7), almost equalling those of breast
cancer patients with bone disease, and a second group
with very low values (median 1.9).
2. Immunohistochemistry
We tested various malignant and benign tissues for the
expression of TRAP (Table 2). The majority of the breast
cancer specimens (15 out of 21), ovarian cancer speci-
mens (6 out of 8) and malignant melanoma specimens (5
out of 6) were found to express TRAP, whereas the corre-
sponding benign tissue showed markedly weaker expres-
sion or none at all. Only one of the 7 cervical cancer
specimens showed TRAP expression.
Figure 2 illutstrates typical immunohistochemical find-
ings. In contrast to normal tissue, the breast cancer speci-
men clearly stained for TRAP (Figures 2a and 2b).
Likewise in serous ovarian carcinoma (Figure 2d), most
tumor cells expressed TRAP, whereas normal celomic
ovarian epithelium was negative (Figure 2c). Figure 2f
shows the only TRAP-positive cervical cancer specimen.
Interestingly, all the cervical cancer specimens exhibited
pronounced infiltration by TRAP-expressing monocytes
(Figure 2f). No TRAP expression could be detected in nor-
mal skin, whereas malignant melanoma cells showed very
strong expression of TRAP (Figures 2g and 2h).
3. Immunocytology
The immunocytological results are summarized in Table 3
and illustrated in Figure 3. Cells cultured from 3 of the 5
malignant pleural effusions in breast cancer patients
expressed TRAP abundantly. The established breast cancer
cell lines MCF 7, MDA-MB-468, HBL-100, and BT20 were
all TRAP positive. Cells cultured from the malignant
ascites of 9 ovarian cancer patients were investigated after
3 to 4 in vitro passages. Five of the cultured cell lines were
TRAP positive. Two established ovarian cancer cell lines,
OAW42 and SKOV3, were also tested and found to
express TRAP, although very weakly.
The malignant melanoma cell lines MV3, BML, and
Mel2A showed marked expression of the TRAP protein,
staining of the BML cells being stronger than that of the
other two cell lines. Of the two cervical cancer cell lines
investigated, SiHA cells showed weak staining for TRAP,
but CaSki cells were negative (data not shown). Of the
two choriocarcinoma cell lines JEG-3 was positive, but
JAR was negative, so that they were used in the RT-PCR
experiments as positive and negative controls, respec-
tively.
4. RT-PCR
In order to confirm TRAP expression in the tumor cells
with another method of detection, RT-PCR analysis of
TRAP mRNA levels in the cell cultures under investigation
was performed. (Figure 4).
Strong expression of TRAP mRNA was found in the two
breast cancer cell lines tested (BT20 and MDA-MB-468)
and in breast cancer cells cultured from pleural effusions
in 2 of the 3 patients investigated. The commercially avail-
able cell lines OAW42 and SKOV3 and ovarian cancer
cells cultured from three patients with malignant ascites
showed a clear PCR product at 171 bp. The two malignant
melanoma cell lines BML and Mel2A both showed TRAP
mRNA expression, which was more pronounced in the
former than in the latter. Repeat RT-PCR experiments con-
sistently revealed TRAP mRNA expression in JEG-3 cells
but none in JAR cells.
Discussion
In contrast to previous studies [1-3], our investigations
revealed high serum concentrations of TRAP not only in
breast cancer patients with bone metastases but also in
such patients with visceral metastases alone.
Our immunohistochemical and immunocytological stud-
ies showed that a broad range of tumor tissues and cells
express TRAP. From our results we conclude that TRAP is
overexpressed in a variety of solid tumors and is most
probably secreted by the tumor cells themselves. The find-
ing that cancer cells express and secrete TRAP is not yet
Analysis of serum of breast cancer patients and controls by  the ELISA technique Figure 1
Analysis of serum of breast cancer patients and controls by 
the ELISA technique. Box and whisker blot of ELISA results 
from patients' serum. C = total control group, VM = visceral 
metastases, BM = bone metastases, B/V = bone and visceral 
metastases.
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well established. Therefore, we evaluated this finding not
only on the mRNA but also on the protein level.
TRAP expression was detected by immunohistochemistry
and RT-PCR in commercially available cell lines and cells
cultured from malignant pleural effusions in breast cancer
patients and in biopsy specimen of breast cancer. Approx-
imately half of the ovarian carcinoma cell cultures derived
from malignant ascites and surgical specimens of ovarian
cancer were positive for TRAP. Likewise, both malignant
melanoma tissue and cell lines clearly expressed TRAP.
On the other hand, TRAP could not be detected in cervical
cancer tissue. TRAP was not detected in the malignant
cells of primary carcinomas of the cervix, but these tumors
showed marked infiltration by TRAP-expressing mono-
cytes.
TRAP expression seems to be confined to malignant tis-
sue, as it was not detected in normal breast or ovarian tis-
sue or normal skin. It appears to be a basic characteristic
of malignant transformation, as it is found in both epithe-
lial and mesenchymal malignancies, such as the malig-
nant melanoma investigated.
TRAP has recently been analyzed in cell cultures and was
detected in both the supernatant medium and cell lysates
[14]. Janckila et al. (2005) demonstrated that both iso-
forms of TRAP are secreted into the supernatant, which
suggests that the high serum values found in our investi-
gation originate from secretion by tumor cells [14]. In
contrast to these authors we did not use cultured cells of
the moncytic lineage to evaluate TRAP levels, but primary
cancer cells and established cell lines from several malig-
nant tumors [14].
Our results are consistent with the recent findings of Chao
et al. (2005), who describe a significant increase in TRAP
in the serum of breast cancer patients with extensive bone
metastases [2]. It can be assumed that the majority of
breast cancer patients with very extensive bone metastases
also have visceral involvement. In the investigation of
Chao and coworkers, patients with limited bone disease
were not found to show increased TRAP concentrations.
Table 3: Immunocytology of commercially available cancer cell lines and cells cultured from malignant pleural effusions and malignant 
ascites. TRAP staining was classified as follows: + positive, (+) weakly positive, - negative.
source cell line TRAP expression
breast cancer cell lines MDA-MB-468 +
MCF-7 +
BT20 +
HBL-100 +
primary breast cancer cells P1 +
P2 +
P3 -
ovarian cancer cell lines OAW42 (+)
SKOV3 (+)
primary ovarian cancer cells A1 +
A2 +
A3 +
cervical cancer cell lines SiHa (+)
CaSki -
melanoma cell lines BML +
Mel2A (+)
MV3 +
Table 2: Immunohistochemical evaluation of TRAP expression in malignant and benign tissue samples.
tissue sample no. of samples no. of TRAP- positive samples
malignant breast cancer 21 15
ovarian cancer 8 6
cervical cancer 7 1
malignant melanoma 6 5
benign normal breast tissue 2 0
normal ovarian tissue 3 0
normal skin 3 0BMC Cancer 2006, 6:199 http://www.biomedcentral.com/1471-2407/6/199
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Immunohistochemical findings in breast, ovarian, and cervical cancer and malignant melanoma, and corresponding benign tissue Figure 2
Immunohistochemical findings in breast, ovarian, and cervical cancer and malignant melanoma, and corresponding benign tissue. 
(magnification 250×) a) Normal breast tissue with no detectable expression of the TRAP protein by immunohistochemistry. 
The brown staining in the duct is due to nonspecific staining of secretions. b) Invasive ductal carcinoma of the breast with sig-
nificant expression of TRAP protein. (brown = DAB) c) Benign ovarian celomic epithelium with no expression of TRAP. d) 
Serous papillary ovarian cancer cells expressing TRAP (brown = DAB). e) No TRAP expression is detectable in non-trans-
formed cervical tissue. f) Only weak expression of TRAP is seen in this cervical cancer specimen. Tumor-infiltrating monocytes 
clearly stain for TRAP, as shown in the enlarged section (brown = DAB). g) No expression of TRAP is detectable by immuno-
histochemistry in normal skin (VIP). The slight brown staining is due to skin pigmentation. h) There is marked overexpression 
of TRAP in the malignant melanoma in the same specimen as in (g), allowing differentiation of the malignant tumor from the 
adjacent normal skin. The slight brown staining is due to skin pigmentation. (purple = VIP)BMC Cancer 2006, 6:199 http://www.biomedcentral.com/1471-2407/6/199
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Immunocytology of cells cultured from pleural effusions and malignant ascites (magnification 400×) Figure 3
Immunocytology of cells cultured from pleural effusions and malignant ascites (magnification 400×). a) Cells cultured from a 
malignant pleural effusion due to metastatic breast cancer. Staining of the cytoplasm for TRAP is seen. P1 b) Cells cultured 
from a malignant pleural effusion due to metastatic breast cancer. with marked expressison of TRAP in most of the cells. P2 c) 
Cells cultured from malignant ascites in a patient with ovarian cancer with obvious staining for TRAP. A1 d) Cells cultured 
from malignant ascites in a patient with ovarian cancer demonstrating staining for TRAP in the cytoplasm. A2 e) The commer-
cially available cell line MCF 7 with staining for TRAP. f) The established cell line OAW42 also shows staining for TRAP. g) The 
malignant melanoma cell line Mel2A with moderate but unequivocal staining for TRAP. h) Malignant melanoma cell line BML 
with staining for TRAP.
A1
OAW-42
A2
MCF-7
P1 P2
Mel2a BMLBMC Cancer 2006, 6:199 http://www.biomedcentral.com/1471-2407/6/199
Page 8 of 9
(page number not for citation purposes)
In addition, their TRAP concentrations were lower than in
patients with visceral metastases alone, although this find-
ing was not statistically significant [2]. This lack of statis-
tical significance is probably due to the small number of
patients with visceral metastases and no bone involve-
ment. Nguyen et al. (1991) described an increase in serum
TRAP values in patients with metastatic breast cancer [4].
Interestingly, this increase was independent of the pres-
ence of bone metastases. This finding can now be
explained by our results.
The cellular function of TRAP and the biological signifi-
cance of its expression in physiological conditions such as
pregnancy or pathological states such as Gaucher's disease
are still not fully understood [15-17]. Our results suggest
that TRAP could serve as a marker of progressive disease,
rather than being a selective marker of bone metastasis.
Future studies may be able to determine whether serum
TRAP concentrations can be used to monitor the success
of chemotherapy. Even more interesting is the possibility
that TRAP could be an attractive target for future cancer
therapies, given its predominant expression in malignant
tissue.
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